Trastuzumab deruxtecan (DS-8201a): the latest research and advances in breast cancer
A Andrikopoulou, E Zografos, M Liontos… - Clinical breast …, 2021 - Elsevier
The development of antibody–drug conjugates composed of a cytotoxic agent and a
monoclonal antibody carrier offers an important alternative to classic chemotherapy
strategies. Trastuzumab deruxtecan (DS-8201a) is a next-generation antibody–drug
conjugate composed of a monoclonal anti-HER2 antibody and a topoisomerase I inhibitor,
an exatecan derivative (DX-8951f). DS-8201a resulted in favorable outcomes in HER2-
positive heavily pretreated breast cancer patients and also had a promising efficacy in …
monoclonal antibody carrier offers an important alternative to classic chemotherapy
strategies. Trastuzumab deruxtecan (DS-8201a) is a next-generation antibody–drug
conjugate composed of a monoclonal anti-HER2 antibody and a topoisomerase I inhibitor,
an exatecan derivative (DX-8951f). DS-8201a resulted in favorable outcomes in HER2-
positive heavily pretreated breast cancer patients and also had a promising efficacy in …